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The rapid and permanent coverage of large full-
thickness skin defects, such as those resulting from 
burns, scar revisions, avulsion injuries, or the excision 
of skin tumors, is a major challenge in burn, plastic 
and reconstructive surgery. The use of autologous 
split-thickness skin grafts is currently the standard 
method for coverage of large defects. However, in 
severe burn injuries, in particular, the shortage of 
donor sites can be a substantial limitation of this 
technique.
The clinical introduction of cultured epithe-
lial autografts (CEAs) in the 1980s helped address 
donor site limitations and improve survival in 
patients with severe burns.1–3 However, more than 
30 years later, despite tremendous research efforts, 
CEA remains fraught with considerable problems 
when used independently for the coverage of deep 
burns, including graft fragility, poor take, susceptibil-
ity to infection, instability of the healed grafts, and, 
ultimately, unsatisfactory long-term functional and 
aesthetic results.4–6 The development of autologous 
bio-engineered dermo-epidermal skin substitutes 
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has provided a promising alternative to CEAs to 
additionally improve the aesthetic and functional 
outcomes in burn treatment.
Boyce et al4–6 added patient’s own fibroblasts 
and keratinocytes on a collagen-glycosaminoglycan 
substrate to produce and clinically test autologous 
dermo-epidermal skin substitutes. Although prom-
ising clinical trials, in terms of graft take and scar 
appearance, have been conducted, these skin substi-
tutes are still not available for commercial use.
Apligraf, a dermo-epidermal skin substitute, 
is FDA approved and commercially available for 
broader clinical application.7–10 However, it is only a 
transient coverage, as it does not consist of patient’s 
own cells, but allogenic human cells.
Therefore, 15 years of laboratory research have 
been invested in our institute in Zurich in the engi-
neering of a bilayered skin substitute. Our research 
team has succeeded in growing a large hydrogel-
based human dermo-epidermal skin construct fea-
turing a multilayered stratified epidermis and a 
near-normal dermis. These grafts have been success-
fully transplanted onto immuno-incompetent rats in 
several preclinical animal studies.11–15
Currently, no comparable, autologous bio-engi-
neered dermo-epidermal skin substitute is commer-
cially available for clinical application. For this reason, 
we cannot rely on former experience regarding clini-
cal handling.16 During the development of the new 
skin substitute in the animal model, grafts were 
enclosed by a small steel ring, which was sutured on 
the back of the rats for protection, and covered with 
simple silicon foil. However, these measures are not 
suitable for clinical use.
Since the newly developed dermo-epidermal skin 
substitute contains cultured autologous epithelial 
cells in addition to fibroblasts, the dressing require-
ments for the clinical application will be at least as 
rigorous as for CEAs. CEAs are highly sensitive to 
tangential forces and infection, both of which are 
directly correlated with poor graft take. Therefore, 
the requirements of a CEA wound dressing are much 
more stringent than those of a split-thickness skin 
graft dressing.17,18 Protection against sheering forces 
and provision of an optimal wound healing micro-
environment are critical to the healing of CEAs. In 
addition, the dressing should exhibit antibacterial 
properties, given the vulnerability of CEAs to bacte-
rial contamination and the associated cytotoxins and 
proteases.19–23 The use of antimicrobial silver-con-
taining dressings is routine in burn treatment.24–26 
However, studies performed to determine whether 
silver is harmful to keratinocytes have revealed mixed 
results.27–31
In summary, the ideal dressing for bio-engineered 
skin combines various characteristics, including pro-
tection against sheering forces, provision of an opti-
mal wound healing microenvironment, antibacterial 
properties, and minimal cytotoxicity. The purpose of 
the current study is to evaluate which dressing best 
unites the aforementioned properties, in preparation 
for the first clinical application of this novel skin ana-
log. In particular, we aim to determine the potential 
cytotoxic effect of dressings containing silver on our 
bio-engineered skin construct.
METHODS
Cell Isolation and Culture
Human split-thickness skin samples were harvested 
after informed consent from patients and/or legal 
guardians was obtained. Human primary ﬁbro-
blasts and keratinocytes were isolated as previously 
described.11 Isolation and cell culture was performed 
in a clean room laboratory class A, in line with good 
manufacturing practice (GMP) guidelines,32 accord-
ing to the deﬁned standard operating procedures 
and in compliance with the established quality man-
agement system. Cell cultures were performed from 
four independent donor samples.
Dermo-Epidermal Skin Substitutes
Human dermo-epidermal skin substitutes comprised 
of human keratinocytes seeded onto collagen type 
I hydrogels with incorporated human dermal ﬁbro-
blasts were created as previously described.33 The 
skin substitutes were engineered in a laboratory class 
A clean room in line with GMP guidelines, accord-
ing to the deﬁned standard operating procedures and 
in compliance with the established quality manage-
ment system (GMP facility of the Wyss Translational 
Center Zurich—Regenerative Medicine Technolo-
gies Platform, Zurich, Switzerland). Brieﬂy, 106 
human primary dermal ﬁbroblasts (passage 2–3) 
were mixed with bovine collagen type I (Symatese, 
France) and neutralized with a buffer containing 
NaOH. The solution was poured into a cell culture 
insert (7 × 8 cm) with a pore size of 3 μm (Oxyphen, 
Switzerland). After incubation for 15 minutes at 
37°C with 5% CO2, the hydrogels were plastically 
compressed.12 The hydrogels were cultivated in 
DMEM supplemented with 10% FCS (Invitrogen, 
Basel, Switzerland). Media changes were performed 
every 2 to 3 days. Five days thereafter, 8 × 106 human 
primary keratinocytes (passage 2–3) were seeded 
onto the complete surface of the hydrogels. Hydro-
gels were cultivated for 5 days with DMEM + 10% 
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FCS in the lower chamber and keratinocyte medium 
(Cell‘n’Tec, Switzerland) in the upper chamber, 
before transplantation onto immuno-incompetent 
rats. For transplantation, round grafts of approxi-
mately 24 mm diameter were cut from the dermo-
epidermal skin substitutes.
Transplantation
All animal experiments were approved by the local 
Committee for Experimental Animal Research. The 
preparation of immuno-incompetent nu/nu rats 
(age 8–10 weeks, Harlan) was performed as previ-
ously described.34 A surgical skin incision on the back 
of the rat was performed, the panniculus carnosus 
was kept intact. Steel rings with a diameter of 26 mm 
were implanted into full-thickness skin defects on 
the back of the rats to prevent wound closure by 
ingrowth of rat skin into the wound area. Grafts 
were transplanted onto the panniculus carnosus into 
the metal rings, ﬁxed with sutures and covered with 
one of the study wound dressings (Figure 1).
Wound Dressings
For coverage of the transplanted skin substitute, 
various wound dressings were used, as summarized 
in Table 1. The wound dressings were in direct 
contact with the epidermis of the skin substitute. 
Any remaining space in the chamber was ﬁlled with 
Jelonet™ (Smith & Nephew, Switzerland). All used 
dressings were applied according to the instructions 
of use. All wound dressings were applied dry, except 
Acticoat™, which was moistened with sterile Aqua 
dest before placement onto the graft. Square pieces 
of Urgotul® and Ligasano® were ﬁxed onto the 
chamber to protect the graft and chamber. As posi-
tive control, skin substitutes were covered with sili-
con foil, which is the standard dressing in our model 
as previously published.11,13–15,33,35
The first dressing change was performed on day 
10. Thereafter, the grafts were covered exclusively 
with silicon foil, since grafts are less susceptible to 
sheering forces and infection at this stage.
Clinical Evaluation
On days 10 and 21, wound dressing changes and 
photographic documentation were performed. The 
percent graft take and presence of local signs of 
infection were assessed at the ﬁrst dressing change 
on day 10. At day 21, the grafts were assessed for 
percent epithelialization and infection. Animals were 
killed 21 days post-transplantation.
Histology
Grafts were excised, halved, and embedded in OCT 
compound (Tissue-Tek®, Sakura Finetek, Japan) or 
ﬁxed in 4% paraformaldehyde (Medite Medizintech-
nik AG, Nunningen, Switzerland) and then embed-
ded in parafﬁn (McCormick, Richmond, VA). Ten 
micrometer parafﬁn sections were cut and stained 
with hematoxylin and eosin (Sigma-Aldrich, Buchs, 
Switzerland).
For immunofluorescence staining, OCT embed-
ded tissue was frozen at −20°C, and sectioned at 
10 μm. Permeabilization was performed in ice-cold 
Figure 1. Schematic diagram of experimental set up. The full-thickness wound (a) is held open by a steel ring (b). The 
transplanted and sutured dermo-epidermal skin substitute (c) is covered with the wound dressing under investigation (d), 
followed by Jelonet™ (e) as needed to ﬁll the chamber, and ﬁnally protected with a layer of Urgotul® (f) and Ligasano® (g).
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acetone for 5 minutes. Thereafter, sections were air-
dried and washed three times in phosphate buffered 
saline (PBS). After blocking with PBS containing 2% 
bovine serum albumin (Sigma) for 30 minutes at 
room temperature, sections were incubated with the 
prelabeled antibodies for 1 hour at room tempera-
ture. Sections were then washed three times with 
PBS, and nuclei were stained with 1 μg/ml Hoechst 
33341 (Sigma) in PBS for 5 minutes at room tem-
perature. Sections were then washed two times with 
PBS, and finally mounted with Dako fluorescent 
mounting solution (Dako, Baar, Switzerland).
Antibodies
The following antibodies were used: anti-human K1 
(clone LHK1, 1:200, Novus Biologicals, Littleton, 
CO); anti-human Lam5α3 (clone P3H9-2, 1:100, 
Santa Cruz, Labforce AG, Nunningen, Switzerland); 
anti-rat CD31 (clone TDL-3A12, 1:50, BD Biosci-
ences Pharmingen, Basel, Switzerland); anti-human 
CD90 (clone AS02, 1:50, Dianova, Hamburg, Ger-
many); anti-human involucrin (clone SY5, 1:100, 
LabVision, Fremont, CA); anti-human loricrin (poly-
clonal, 1:500, Abcam, Cambridge); anti-rat CD11b 
(macrophage marker, 1:50, Santa Cruz, Labforce 
AG), and anti-rat HIS48 (granulocyte marker, 1:50, 
Santa Cruz, Labforce AG).
For immunofluorescence staining, primary anti-
bodies were prelabeled with either Alexa488 or 
Alexa555 conjugated polyclonal goat F(ab′)2 frag-
ments, according to the manufacturer’s instructions 
(Zenon Mouse IgG Labelling Kit, Molecular Probes, 
Invitrogen, Basel, Switzerland).
Microscopy
The histochemical and immunoﬂuorescence stain-
ings were analyzed with a Nikon Eclipse TE2000-U 
inverted microscope, equipped with Hoechst, FITC 
and TRICT ﬁlter sets and connected with a DXM1200F 
digital camera (Nikon AG, Egg, Switzerland).
RESULTS
A total of 18 rats were studied. The breakdown by 
dressing group is shown in Table 1.
Macroscopic Appearance of Epidermis on 
Transplanted Grafts
Graft take of 100% with complete epithelialization 
was observed at 10 days for all dressing groups, 
including Vaseline Gauze™, Suprathel®, Urgotul® 
SSD, Mepilex® AG, and Acticoat™ (Figure 2, sec-
ond column). This is comparable to the positive 
control of grafts covered with silicon foil (data not 
shown), as previously published.11,13–15,33,35 No signs 
of local infection were observed. On grafts covered 
with Vaseline Gauze™, Urgotul® SSD, or Acticoat™, 
imprints of the mesh structure of the dressing were 
visible, whereas grafts covered with Mepilex® AG 
and Suprathel® did not show any imprint of the 
wound dressing.
Table 1. Overview on used dressing materials
Dressing Manufacturer Composition Silver Content
Number of 
Animals
Dressing material in direct contact with the skin substitute
  Vaseline Gauze™ Kendall Gauze impregnated with petrolatum (8884 413605, 
7.6 × 22.9 cm)
– 3
  Suprathel® PolyMedics Innovations 
GmbH
Lacto-capromer tetrapolymer – 3
  Urgotul® SSD URGO Medical Polyester mesh impregnated with dispersion of 
carboxymethyl cellulose, petroleum jelly, silver 
sulfadiazine particles
0.35 mg/cm2 4
  Mepilex® AG Mölnlycke Health Care Polyurethane foam, polyethylene release ﬁlm, silicone 
gel, silver sulfate, activated charcoal
1.2 mg/cm2 4
  Acticoat™ Smith & Nephew Polyethylene nets coated with nanocrystalline silver, 
absorbent inner core
1.0–1.2 mg/cm2 4
Dressing material not in direct contact with the skin substitute
  Jelonet™ Smith & Nephew Low adherent, parafﬁn impregnated tulle gras dressing 
made from open weave gauze
– –
  Ligasano® Ligamed medical Produkte 
GmbH
Polyurethane foam – –
  Urgotul® URGO Medical Polyester mesh impregnated with dispersion of 
carboxymethyl cellulose, petroleum jelly
– –
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Figure 2. Macroscopic appearance of transplanted skin grafts. The macroscopic appearance of transplanted dermo-epidermal 
skin grafts at day of transplantation (left column), 10 days post-transplantation (middle column), and 21 days post-trans-
plantation (right column) is shown. All transplants have a similar appearance on the day of transplantation. For transplants 
covered with Vaseline Gauze™, Suprathel®, Urgotul® SSD, or Mepilex® AG, at 10 and 21 days post-transplantation the 
surface appears dry and dull. The surface of transplants covered with Acticoat™ appears to be less stable 10 and 21 days 
post-transplantation and inter-animal variations are higher (therefore representative apparent positive and apparent negative 
outcomes with Acticoat™ are shown). Diameter of metal ring is 26 mm.
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At day 21, no signs for infection could be observed, 
and complete epithelialization was seen macroscopi-
cally for all groups (Figure 2, third column). Grafts 
covered with Acticoat™ showed diverse appearances 
macroscopically, in contrast to the more consistent 
appearance of grafts in the other groups (Figure 2, 
bottom two rows).
Histological Analysis of Grafts Excised 21 
Days Post-Transplantation
Hematoxylin & eosin stainings of cryosections 
revealed a multilayered, stratiﬁed epidermis, includ-
ing a stratum corneum, for all samples (Figure 3). No 
signiﬁcant differences could be identiﬁed between 
the various wound dressing groups. Interestingly, 
excised grafts covered with Acticoat™ also showed a 
well stratiﬁed epidermis, in spite of the variable mac-
roscopic appearances (Figure 2).
Immunoﬂuorescence Analysis
The immunoﬂuorescence stains for the basal lamina 
component laminin 5 revealed a continuous deposi-
tion of a basement membrane in all grafts, independent 
of the wound dressing used (Figure 4, left column). 
Stains for keratin 1 showed expression of keratin 1 in all 
suprabasal cell layers of the epidermis, indicating cor-
rect stratiﬁcation in all groups (Figure 4, left column).
Expression of human-specific CD90 confirmed 
the presence of human dermal fibroblasts in all 
groups. Ingrowth of host blood vessels into the 
transplanted grafts, as detected by rat-specific CD31 
staining, could be observed in all groups. Rat blood 
vessels in the human graft, in close proximity to 
the epidermis, were observed in samples from the 
Vaseline Gauze™-, Suprathel®-, Urgotul® SSD-, 
and Acticoat™-groups (Figure 4, right column). In 
samples from the Mepilex® AG-group, blood ves-
sels were detected in the graft but not as close to 
the surface of the graft as was observed for the other 
groups.
In healthy human epidermis, involucrin is 
expressed in the epidermis from the last layer of 
the stratum spinosum to the first layers of the stra-
tum granulosum. In all grafts, continuous involu-
crin expression was observed in the upper layers of 
the newly formed epidermis. Loricrin expression, a 
marker for cornified epithelial cells, was also similar 
in all grafts.
Granulocytes were stained with the granulocyte 
marker HIS48. Almost no granulocytes were found 
in the grafts. In samples covered with Acticoat™, 
some granulocytes could be detected (Figure 5, left 
column).
Host macrophages were stained with the macro-
phage marker integrin CD11b. No macrophages 
Figure 3. Histologic appearance of transplanted skin grafts. The histologic appearance of transplanted dermo-epidermal skin 
grafts 21 days post-transplantation is shown. Hematoxylin and eosin staining reveals a multilayered, stratiﬁed, and corniﬁed 
epidermis for all samples. No differences can be observed regarding layers or status of stratiﬁcation. Scale bars 50 μm.
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Figure 4. Immunoﬂuorescence analysis of transplanted skin grafts. Immunoﬂuorescence stainings of transplanted dermo-
epidermal skin grafts 21 days post-transplantation are shown. Keratin 1 expression (left column, green) was found in the 
suprabasal layers of all grafts. In all grafts, a continuous basement membrane was deposited as revealed by staining for the 
basement membrane component laminin 5 (left column, red). Remnants of the human graft could be detected by staining 
for human ﬁbroblast-speciﬁc CD90 (right column, green) in all grafts. Rat blood vessels, as detected with rat-speciﬁc CD31 
(right column, red), grew into the graft in all samples. Scale bars 50 μm.
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Figure 5. Immunoﬂuorescence analysis for leukocytes in transplanted skin grafts. Immunoﬂuorescence stainings of trans-
planted dermo-epidermal skin grafts 21 days post-transplantation are shown. Continuous loricrin expression was found in 
all grafts (left column, green). Granulocytes were stained with the granulocyte-speciﬁc marker HIS48. Only in Acticoat™-
samples could some granulocytes be detected (left column, red). Involucrin expression was found in upper layers of the epi-
dermis (right column, green). Macrophages were stained with the macrophage-speciﬁc marker CD11b, but no macrophages 
were detected in the grafts (right column, red). Scale bars 50 μm.
Copyright © American Burn Association. Unauthorized reproduction of this article is prohibited.
Journal of Burn Care & Research 
Volume XXX, Number XXX Hüging et al  9
were detected in any of the grafts (Figure 5, right 
column). For all stainings, rat skin was used as a posi-
tive control (data not shown).
DISCUSSION
In several previous studies we demonstrated the 
use of our newly developed bio-engineered human 
dermo-epidermal skin substitute in preclinical in vivo 
assays.11,13–15,33 Our model offers the possibility to 
transplant human hydrogel-based dermo-epidermal 
skin substitutes, which is unique and not compa-
rable to any other model. Other authors have used 
plastic chambers transplanted onto mice, therefore 
the human skin substitutes were much smaller,36 or 
sutured human skin directly to the mice skin without 
any physical demarcation by ring or chamber, not 
preventing ingrowth of mice skin.37 We continuously 
modiﬁed and improved our skin constructs in order 
to obtain the best overall biological properties (eg, 
stability against sheering forces, promotion of vascu-
lar ingrowth). We were able to produce dermo-epi-
dermal skin substitutes on a large scale by employing 
plastically compressed collagen hydrogels.12,38,39
The aim of this study was to determine the effect 
of several wound dressings, which are commonly 
used for skin graft coverage, on our dermo-epider-
mal skin constructs in our in vivo transplantation 
model. The investigation was conducted in prepa-
ration for the upcoming first-in-human study. We 
investigated 3 wound dressings containing silver 
(Acticoat™, Mepilex® Ag, and Urgotul® SSD) and 
2 without silver (Suprathel® and Vaseline Gauze™). 
These dressings had already been investigated in 
preclinical studies regarding their adverse effects on 
cells,21,22,40,41 bacteria,42–44 created wounds,45,46 and 
in clinical applications.47–53
At day 10 we observed a graft take of 100%. After 
21 days, the same macroscopic results were found, 
and histologically, every specimen demonstrated 
a stratified and cornified epidermis. This was sup-
ported by the presence of epidermal differentiation 
markers, such as CK1, involucrin, and loricrin. Host 
blood vessels were detected in the human dermal part 
of all the transplanted skin substitutes. In samples 
from the Mepilex® AG-group, blood vessels were 
detected in the graft, but not as close to the surface 
as was seen with the other groups. Based on experi-
ence, this might be due to inter-animal variations, 
rather than the wound dressing used. Rat immune 
cells, such as granulocytes and macrophages, could 
be detected only rarely, highlighting that the human 
skin substitutes are well-accepted in this model. To 
summarize, a well-vascularized human dermis was 
established by the host vasculature without any signs 
of immune reaction in all transplants using silver and 
non-silver-containing wound dressings. This was 
also observed in our previous studies when only a 
silicon foil dressing was applied.35,54
Our dressing schedule deserves a more detailed 
comment. After 10 days we changed the wound 
dressing in every specimen to silicone foil, since 
there is no beneficial effect of silver dressings with 
respect to infection or wound healing after this time 
period, as per the current literature.55,56
Importantly, none of the tested wound dress-
ings reduced the survival or number of human 
epithelial cells within the skin substitutes. This is 
particularly notable for the silver-containing dress-
ings, which have demonstrated a cytotoxic effect in 
previous studies. The study by Esteban-Vives et al57 
described a negative effect of Mepilex AG® on kera-
tinocyte attachment and survival in vitro. Moreover, 
in the current study, the formation of a multilayered 
stratified epidermis was not hampered, either with 
or without silver, which has also been described 
previously.21,22,40,41
Also of note, we observed an imprint of the mesh 
structure of Vaseline Gauze™, Urgotul® SSD, and 
Acticoat™ onto the skin substitutes. This was a tran-
sient finding and did not affect the epidermal struc-
ture or biological viability.
We did not investigate the presence of released, 
absorbed, or distributed silver in the host organism 
during the study. Related investigations have previ-
ously been performed by others.21,22,46 Nonetheless, 
we also have to take into account that we used an 
excisional wound model on athymic nude rats to test 
our human dermo-epidermal skin substitutes. Val-
vis et al58 in a mouse model (using C57BL/6 mice) 
showed significant differences between immune 
responses in mice comparing burn and excisional 
injuries. They observed an acute neutrophil attrac-
tant with a delayed macrophage promoting environ-
ment in the excisional injury, compared to an early 
macrophage promoting environment after a burn 
injury.
However, we used athymic rats and applied human 
cellularized skin substitutes onto excisional created 
wounds also affecting the wound healing response, 
and tested for macrophages and granulocytes only at 
a later time point but not at the acute wound healing 
phase. Of course, our preclinical animal experiments 
give hints about possible processes taking place in a 
skin wound healing situation but are not completely 
comparable to a clinical human situation.
In conclusion, all herein tested dressings 
applied on our clinically GMP grade human 
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dermo-epidermal skin substitutes yielded a satisfy-
ing outcome regarding graft take, epithelialization, 
and infection control. Therefore, all tested wound 
dressings would be suitable for use in the foreseen 
phase I clinical trial. Furthermore, our large autolo-
gous skin substitutes demonstrated stability in com-
bination with every tested dressing. Concerns about 
the cytotoxicity of silver were not validated during 
the study. In fact, we observed reproducible results 
with excellent graft take with the silver-containing 
dressings. If there is widespread use of our skin sub-
stitutes in the future, this study supports the use of 
silver-containing dressings, particularly when infec-
tion control is necessary.
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